Clinical Trial: A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07920731) titled 'A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer' on Oct. 29.

Brief Summary: This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients. All patients will receive nimotuzumab combined with the NALIRIFOX chemotherapy regimen as first-line treatment.

Nimotuzumab is a targeted antibody against EGFR. NALIRIFOX is a standard first-line chemotherapy regimen for advanced pancreatic cancer and includes liposomal irinotecan, oxaliplatin, leucovorin, and 5-FU. Nim...